Picture of Altamira Therapeutics logo

CYTO Altamira Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-24.5%
3m-38.18%
6m-65.66%
1yr-93.75%
Volume Change (%)
10d/3m-94.65%
Price vs... (%)
52w High-93.49%
50d MA-25.28%
200d MA-62.36%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-86.94%
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Altamira Therapeutics EPS forecast chart

Profile Summary

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    March 18th, 2019
    Public Since
    August 6th, 2014
    No. of Shareholders
    4
    No. of Employees
    10
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    2,240,245

    CYTO Share Price Performance

    Upcoming Events for CYTO

    Half Year 2024 Altamira Therapeutics Ltd Earnings Release

    Similar to CYTO

    Picture of 180 Life Sciences logo

    180 Life Sciences

    us flag iconNASDAQ Capital Market

    Picture of Abeona Therapeutics logo

    Abeona Therapeutics

    us flag iconNASDAQ Capital Market

    Picture of ABVC Biopharma logo

    ABVC Biopharma

    us flag iconNASDAQ Capital Market

    Picture of Acesis Holdings logo

    Acesis Holdings

    us flag iconNASDAQ Capital Market

    Picture of Achieve Life Sciences logo

    Achieve Life Sciences

    us flag iconNASDAQ Capital Market

    FAQ